ACC-001
ACC-001 is a biological therapy with 5 clinical trials. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Clinical Trials (5)
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5